摘要
目的研究丹参类制剂在脑出血急性期治疗方面的安全性。方法 144例急性期高血压脑出血治疗患者,将其分为试验组87例和对照组57例,试验组采取丹参类制剂进行治疗,对照组采取常规的西医治疗方法,治疗后对瘫痪肢体运动功能予以《中国神经功能缺损评定标准》进行评分。结果在住院天数、病死率以及神经功能缺损评分方面,试验组都优于对照组,差异有统计学意义(P<0.05)。结论丹参类制剂对脑出血急性期的治疗和早期康复介入安全性高,在患者神经功能方面的恢复、病死率和致残率的降低方面都能起到较好的作用,值得进行临床推广。
Objective To investigate the safety of Danshen preparation on acute phase of cerebral hemorrhage. Meth- ods 144 cases of patients with acute phase of cerebral hemorrhage were randomly divided into the experimental group （87 cases） and control group （57 cases）. The experimental group was treated with Danshen preparation,while the control group was given conventional western medical treatment. After the treatment, the motor function of paralysis limb was scored according to Chinese neural hmction defect assessment standards. Results The experimental group was better than the control group in as- pects of hospital stay,mortality and neurological deficit score, and the difference was statistically significant （P 〈 0.05）. Con- dusions Dansben preparation has high security on acute cerebral hemorrhage treatment and early rehabilitation, can play a better role on neurological function recovery of patients,the fatality rate and mutilation rate reduction,which is worthy of clini- cal promotion.
出处
《临床合理用药杂志》
2013年第32期7-8,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
丹参类制剂
脑出血急性期
安全性
Danshen preparation
Acute phase of cerebral hemorrhage
Safety
